MannKind is expected to report third-quarter 2026 revenue of $107.74 million (+31.2% YoY) and a consensus EPS of -$0.06, while the stock currently trades near $3.50 compared to an $8.08 average analyst price target.
Investors are specifically monitoring Tyvaso DPI royalty growth and the commercial uptake of pediatric Afrezza following its recent FDA approval and 2026 launch. The company is currently scaling its commercial infrastructure to support the rollout of FUROSCIX ReadyFlow while managing elevated commercialization expenses.
Analysts are evaluating MannKind’s shift toward a more diversified revenue model and its progress in advancing the Phase 2 nintedanib pipeline for orphan lung diseases.